The tech company plans to premiere its first product at the convention in January in Las Vegas, Nevada
FluxWear, a neuromodulation technology company, announces that it will be demonstrating its first product at the Consumer Electronics Show in Las Vegas on January 5-8, 2022. The product, SHIFT, is a wearable neuromodulation device that allows those suffering with pain, anxiety, or stress to rapidly attain a meditative state and experience the benefits of meditation.
Recommended AI News: Aqua Security Achieves AWS Graviton Ready Designation
SHIFT delivers a unique magnetic stimulation profile resulting in rapid functional connectivity improvements within targeted brain networks that quickly place the user in a relaxed meditative state – all in a discrete, comfortable cadet-style cap. Once in this state, the user can attain the health benefits of meditation including reduced pain, decreased stress, deeper sleep, and improved focus.
“We are thrilled to be taking our product to CES to show the world what this technology is truly capable of,” says Kamran Ansari, co-founder of FluxWear and inventor of SHIFT. “We sincerely believe that this device will make the benefits of meditation accessible to all and change the lives of millions who suffer from chronic pain and anxiety.”
Recommended AI News: Okera Expands Its Footprint with AWS to Power Universal Data Authorization
In 2017, Kamran’s sister and co-founder, Nadia Ansari, was diagnosed with an autoimmune disease which caused her severe chronic pain. Determined to help his sister, Kamran began a journey to develop a product that would help Nadia achieve a meditative state to better manage her pain. After creating the initial prototype in 2020, Kamran and Nadia experimented and eventually developed a stimulation profile that, within minutes, enabled Nadia to enter into a deep meditative state and reduce her pain as a result.
FluxWear will be demonstrating SHIFT in the Westgate Hotel and will be scheduling exclusive, one-on-one SHIFT mediation sessions for media.
Recommended AI News: Gilead And AWS Collaborate On Development And Delivery Of New Medicines For Patients
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.